DHTKD1 and breast carcinoma: Our results demonstrate that E1A gene therapy can sensitize breast cancer cells to EGFR-TKI both in vitro and in vivo, suggested that E1A may improve the current poor prognosis in breast cancer patients, and it may be a useful strategy to increase the anti-tumor activity of EGFR-TKI in breast cancer patients.